Indian Journal of Psychological Medicine
Users Online: 221 
  Home | About Us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Contact | Advertise | Submission | Login 
Wide layoutNarrow layoutFull screen layoutHome Print this page Email this page Small font sizeDefault font sizeIncrease font size


 
 Table of Contents    
CASE REPORT
Year : 2018  |  Volume : 40  |  Issue : 6  |  Page : 577-579  

Lithium-induced thyroiditis in a patient having bipolar affective disorder - A rare case report


Department of Psychiatry, Amrita Institute of Medical Sciences and Research Institute, Kochi, Kerala, India

Date of Web Publication9-Nov-2018

Correspondence Address:
Dr. Kotchuthressia Mathew
Department of Psychiatry, Amrita Institute of Medical Sciences and Research Institute, Kochi, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJPSYM.IJPSYM_403_17

Rights and Permissions
   Abstract 


A 22-year-old female, previously diagnosed with bipolar affective disorder on lithium therapy, presented to us with manic symptoms. The blood investigations revealed elevated thyroxine and thyroid peroxidase antibodies and reduced thyroid-stimulating hormone with poor tapping function of thyroid on technetium thyroid scintigraphy indicating lithium-induced thyroiditis.

Keywords: Bipolar affective disorder, lithium, thyroiditis


How to cite this article:
Arathil P, Mathew K, Narayanan D. Lithium-induced thyroiditis in a patient having bipolar affective disorder - A rare case report. Indian J Psychol Med 2018;40:577-9

How to cite this URL:
Arathil P, Mathew K, Narayanan D. Lithium-induced thyroiditis in a patient having bipolar affective disorder - A rare case report. Indian J Psychol Med [serial online] 2018 [cited 2018 Dec 19];40:577-9. Available from: http://www.ijpm.info/text.asp?2018/40/6/577/245087




   Introduction Top


Lithium is the gold standard agent used in bipolar affective disorder. One of the clinical adverse effects of lithium is goiter in up to 40% due to inhibition of thyroid hormone secretion in significant number of patients receiving the drug for treatment of bipolar disease.[1] Clinically, there is thyroid enlargement and low triiodothyronine (T3), thyroxine (T4) levels. Cases of hyperthyroidism have also been associated with its treatment but are rare compared with hypothyroidism and goiter. Silent thyroiditis has been rarely associated with lithium therapy. The following case presents silent thyroiditis where serum T4 was elevated with low thyroid-stimulating hormone (TSH) value.


   Case Report Top


Ms L, a 22-year-old single female, educated till the 12th standard is a known case of bipolar affective disorder for 17 years of age with two episodes of mania in the years 2013 and 2015. She was maintaining well on lithium (800 mg/day). Serum lithium levels and thyroid function tests were within normal limits even 3 months before the current episode. She had a family history of hypothyroidism in maternal grandmother who was on thyroid supplementation.

In April 2017, she was brought to the psychiatry department by her parents with a history of increased activity, reduced sleep, over-talkativeness, and anger outbursts toward family members for 1 week. After admission, detailed assessment was done. On physical examination, proptosis was evident. Mild lid lag was present. She had a fine tremor of hands and warm extremities. There was an increased volume in her speech and her affect was irritable. However, she had normal goal-directed psychomotor activity and cognitive functions were intact. She had grade 2 insight. The clinical features were suggestive of manic episode. On initial investigations, her serum electrolytes, hemogram, hepatic, and renal function tests were normal. Serum lithium quantitative analysis was done and levels were within therapeutic range (0.65 mEq/L). Her serum T4 was elevated (3.10 ng/dl) and TSH was low (0.0049uIU/ml). Endocrine consultation was sought, and thyroid peroxidase antibody was evaluated, which showed elevated values (594.80 U/ml). Technetium thyroid scintigraphy was suggested for further evaluation. Poor tapping function of the thyroid gland was evident in scintigraphy, and a diagnosis of iatrogenic thyroiditis was made by the endocrinologist. Propranolol 40 mg was started by the endocrinology department for hyperthyroidism. She was continued on lithium 800 mg/day as mood stabilizer and amisulpride 200 mg for control of acute manic symptoms. By discharge 10 days later, the patient had improved significantly in regard to the manic symptoms.

In the subsequent follow-up after 1 month, the results of her thyroid function tests were as follows T3, 4.90 ng/dl (1.31–3.71); TSH, 0.0018 μIU/ml serum (0.35–4.9); and thyroid peroxidase antibody (TPO) 594, which were suggestive of a diagnosis of iatrogenic thyroiditis (lithium induced). The patient was started on carbimazole 10 mg by the endocrinology. She was continued on lithium 800 mg, amisulpride 200 mg, and propranolol 40 mg. Her TPO levels reduced after initiation of carbimazole therapy. In the subsequent review after 3 months, her TPO levels normalized.


   Discussion Top


Lithium is effective in acute mania and in prevention of recurrence. The main indication for lithium is in prophylaxis of bipolar affective disorder where it reduces both the number and severity of relapses. The minimum effective plasma level for prophylaxis is 0.4 mmol/L with optimal range being 0.6–0.75 mmol/L. The drug has multiple effects on thyroid function. Lithium blocks the release of thyroid hormone from the thyroid gland which leads to goiter and hypothyroidism. The reported prevalence of hypothyroidism is estimated to be about 20%.[2],[3] There have only been sporadic cases of hyperthyroidism among the patients treated with lithium.[3],[4] Lithium-associated thyroiditis has rarely been described in the literature.[1],[5] In the clinical setting, thyroiditis after initiating lithium therapy is rare, and only three cases of lithium-associated thyroiditis and four cases of autoimmune thyroiditis have been reported.[6] Lithium induces sporadic thyroiditis by direct toxic effects. It directly damages thyroid cells, with consequent release of thyroglobulin and thyroid hormones into the circulation; therefore, thyrotoxicosis caused by silent thyroiditis might be associated with lithium use.[1]

The differential diagnosis for hyperthyroidism included Grave's disease. The classical scintigraphy pattern of Grave's disease is homogeneous increase in radiotracer uptake in both lobes of the thyroid gland. In contrast, the distribution pattern of radiotracer is reduced in silent thyroiditis where the follicles are disrupted suggestive of iatrogenic thyroiditis (lithium induced). Radioactive iodine uptake is high in Grave's disease and low in thyroiditis. Histologically, painless thyroiditis resembles autoimmune thyroiditis, but according to Mizukami et al.[4] stromal fibrosis and Hurthle cells are rare in the former.

Before initiating prophylaxis with lithium in bipolar affective disorders, the assessment of thyroid function is recommended for all patients; the assessment should include plasma levels of TSH and antithyroid antibodies.[7] Determination of free T4 should be added in cases in which TSH is suppressed (to rule out central hyperthyroidism or hypothyroidism) or elevated (to confirm the presence of hypothyroidism). Once treatment with lithium salt has commenced, the analytic determinations to study thyroid functions should be repeated every year. It is necessary to re-establish the euthyroid state so that secondary psychiatric symptoms remit.


   Conclusion Top


It becomes imperative to rule out thyroid disorders in all bipolar affective disorder patients as thyroiditis and mania shows similar symptoms. For every episode of mania in bipolar affective disorder, thyroid function tests must be carried out. Proper therapy helps control the progress of thyroid disorder and prevents relapse in bipolar affective disorder patients on lithium therapy.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009;23:723-33.  Back to cited text no. 1
    
2.
Ricken R, Bermpohl F, Schlattmann P, Bschor T, Adli M, Mönter N, et al. Long-term treatment with supraphysiological doses of thyroid hormone in affective disorders – Effects on bone mineral density. J Affect Disord 2012;136:e89-94.  Back to cited text no. 2
    
3.
McDermott MT, Burman KD, Hofeldt FD. Lithium associated thyrotoxicosis. Am J Med 1986;80:1245-8.  Back to cited text no. 3
    
4.
Mizukami Y, Michigishi T, Nonomura A, Nakamura S, Noguchi M, Takazakura E. Histological features of the thyroid gland in a patient with lithium induced thyrotoxicosis. J Clin Pathol 1995;48:582-4.  Back to cited text no. 4
    
5.
Barclay ML, Brownlie BE, Turner JG, Wells JE. Lithium associated thyrotoxicosis: A report of 14 cases, with statistical analysis of incidence. Clin Endocrinol (Oxf) 1994;40:759-64.  Back to cited text no. 5
    
6.
Calabrese JR, Gulledge AD, Hahn K, Skwerer R, Kotz M, Schumacher OP, et al. Autoimmune thyroiditis in manic-depressive patients treated with lithium. Am J Psychiatry 1985;142:1318-21.  Back to cited text no. 6
    
7.
Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry 2001;178 Suppl 41:S184-90.  Back to cited text no. 7
    




 

Top
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Report
   Discussion
   Conclusion
    References

 Article Access Statistics
    Viewed99    
    Printed2    
    Emailed0    
    PDF Downloaded20    
    Comments [Add]    

Recommend this journal